沙库巴曲缬沙坦在射血分数降低性心力衰竭患者治疗中的研究进展

Sacubitril-valsartan for Heart Failure with Reduced Ejection Fraction

射血分数降低性心力衰竭约占心力衰竭患者的50%。尽管既往针对射血分数降低性心力衰竭患者治疗的药物研究已取得多个突破,但射血分数降低性心力衰竭患者的5年生存率仍不足50%。沙库巴曲缬沙坦是一种血管紧张素受体和脑啡肽酶的双重抑制剂,PARADIGM-HF等研究证实沙库巴曲缬沙坦能较依那普利进一步降低患者的心血管死亡和心力衰竭住院率,且不良事件发生率低,并在糖尿病、低血压、无法耐受靶剂量治疗等特殊的射血分数降低性心力衰竭患者群体中具有良好的疗效。

Heart failure with reduced ejection fraction(HFrEF)accounts for about 50%of heart failure patients.Although several breakthroughs got on the treatment of HFrEF,the 5-year survival rate of these patients is still less than 50%.Sacubitril-valsartan(LCZ696)is a dual inhibitor of angiotensin receptor and neprilysin.PARADIGM-HF and other researches confirmed that LCZ696 can further reduce the incidence of cardiovascular death and heart failure hospitalization than enalapril,as well as lower adverse events.In patients combined with diabetes,hypotension or who take less than target doses it also showed good effectiveness.